FIELD: biotechnology.
SUBSTANCE: invention relates to recombinant production of fusion proteins binding glypican-3 (GPC3) and differentiation cluster 137 (CD137) and can be used in medicine for therapy of GPC3-positive forms of cancer. Disclosed is a fused protein which includes a full-length immunoglobulin which specifically binds to GPC3, connected from the C-terminus by a peptide linker to the N-terminus of a lipocalin mutein which specifically binds to CD137.
EFFECT: invention enables to obtain a fusion protein capable of simultaneously specifically binding both CD137 and GPC3.
15 cl, 11 dwg, 11 tbl, 14 ex
| Title | Year | Author | Number |
|---|---|---|---|
| FUSED POLYPEPTIDE WITH ANTI-CANCER ACTIVITY | 2016 |
|
RU2754466C2 |
| MUTEINS OF HUMAN LIPOCALIN 2 WITH AFFINITY FOR GLYPICAN-3 (GPC3) | 2016 |
|
RU2756318C2 |
| NOVEL FUSION PROTEIN SPECIFIC FOR CD137 AND PD-L1 | 2019 |
|
RU2818349C2 |
| NOVEL SPECIFIC BINDING POLYPEPTIDES AND ROUTES OF USE THEREOF | 2015 |
|
RU2723034C2 |
| PROTEINS SPECIFIC FOR CD137 | 2016 |
|
RU2736312C2 |
| NOVEL PROTEINS SPECIFIC FOR ANGIOGENESIS | 2016 |
|
RU2720688C2 |
| HUMAN LIPOCALIN 2 MUTEINS (Lcn2, hNGAL) WITH TARGETED AFFINITY | 2019 |
|
RU2804336C2 |
| HUMAN LIPOLOCAL 2 MALLETES (LCN2, HNGAL) WITH AFFINITY FOR SPECIFIC TARGET | 2010 |
|
RU2707126C2 |
| CYTOTOXICITY-INDUCING THERAPEUTIC AGENT | 2022 |
|
RU2824285C2 |
| IMMUNOACTIVATING ANTIGEN-BINDING MOLECULE | 2015 |
|
RU2722788C2 |
